Desarrollo de un modelo preclínico de úlcera de pie diabético en cerdo miniatura Göttingen
- Celdrán Bonafonte, Diego
- Francisco Miguel Sánchez Margallo Directeur/trice
- María Fernanda Martín Cancho Directeur/trice
Université de défendre: Universidad de Extremadura
Fecha de defensa: 31 mars 2004
- Jesús Usón Gargallo President
- Rafael Manuel Latorre Reviriego Secrétaire
- Rafael Barrera Chacón Rapporteur
- José L. Jorcano Noval Rapporteur
- José Luis Pedraz Muñoz Rapporteur
Type: Thèses
Résumé
Animal models are a cornerstone of modern medical and pharmaceutical research. The development of animal models of human diseases is essential to test the effectiveness of new treatments and their advantages over the existing ones. The high current prevalence of diabetes highlights the need for obtaining reproducible animal models that recreate as faithfully as possible the main features of the disease and its complications. The treatment of one of its complications, diabetic foot ulcer, remains a challenge for clinicians, and a reliable and reproducible animal model is required in order to test the effectiveness of new treatments for impaired skin regeneration. During the last years, the porcine model has overtaken other species in the role of being the reference non-rodent model for preclinical studies, because of its anatomic and phsiologic similarity with humans. On this study we have developed a diabetic foot ulcer model in the hind legs of diabetic-dyslipemic Göttingen minipigs, providing detailed basal kinetic data from the healing, in order to be used as valuable platform to support the development of new therapies and treatments for chronic diabetic ulcers. The proposed model reproduces several clinical features from human diabetic wound, the lack of uniformity on the published diabetic dislipemia protocols and the absence of basal data from diabetic wound healing in Göttingen minipigs makes this study a good first step in the establishment of a reliable and reproducible diabetic ulcer large animal model in order to support the development and test the efficacies of new treatments and therapies.